Skip to content
Promakhos Therapeutics logo

Promakhos Therapeutics

Promakhos Therapeutics is a YC Summer 2021 (S21) company. Based in Boston, MA, USA. Team of 2.

  • Therapeutics

About Promakhos Therapeutics

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Promakhos Therapeutics develops a platform of bacterial molecules designed to restore the immune system's natural ability to control inflammation, rather than suppressing it. The company targets chronic inflammatory diseases, with Crohn's disease as its first indication, followed by type 1 diabetes and multiple sclerosis. Current standard-of-care therapies manage symptoms by dampening immune activity; Promakhos aims to address the underlying dysfunction instead.

From the Y Combinator listing

How Promakhos Therapeutics describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

A therapeutics platform for curing inflammatory disorders

We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Boston, MA, USA
Team size
2
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works